Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing ActivitySummary
GBI Research has released its latest research, “Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity” which provides insights into the licensing agreements of large pharmaceutical companies. The report provides an in-depth analysis of the major licensing agreement trends in the pharmaceutical industry along with product and technology licensing trends. In addition, the report also analyzes the top 20 pharmaceutical companies with respect to the licensing agreement activities.
The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.Scope
The scope of this report includes -
Reasons to buy
- Major market trends that are expected to shape the licensing and deal making landscape in pharmaceutical industry
- Trends in deals for product licensing and technology licensing agreements.
- Extensive research and analysis of the licensing activity of large pharmaceutical companies.
- Licensing and deal making segmentation of top 20 in the pharmaceutical companies by phase, type, geography and value
- Company profiles of leading biotech companies active in licensing and deal making
The report will enhance your decision making capability. It will allow you to -
- Develop market-entry and market expansion strategies by identifying the leading areas for licensing and deal making in the pharmaceutical industry.
- Enable better product lifecycle management by identifying key phases of product licensing agreements.
- Develop segment specific strategies for licensing and deal making in pharmaceutical industry.
- Develop key strategic initiatives by understanding the key licensing and deal making focus areas of leading pharma companies.
- Accelerate and strengthen your market position by identifying key companies for licensing agreements.